FDA has granted Priority Review to capmatinib's (INC280) New Drug Application.
FDA has granted Breakthrough Therapy designation for Padcevtm in combination with Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.
FDA has accepted the Biologics License Application of valoctocogene roxaparvovec for Priority Review.
The phase III CheckMate -025 study demonstrated that treatment with Opdivo (nivolumab) continues to deliver superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma, compared to those treated with everolimus.
Although one in seven adults smoke cigarettes the year prior to undergoing weight-loss surgery, nearly all successfully quit at least a month before their operation. However, smoking prevalence steadily climbs to pre-surgery levels within seven years, according to new research led by the University of Pittsburgh Graduate School of Public Health.
We were recently presented with the new report from American Cancer Society1 showing the biggest annual decrease in cancer mortality, which was mainly due to decline in smoking, as well as improvements in early detection and treatment.
Pamela L. Kunz was named leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center, and director of GI Medical Oncology within the Section of Medical Oncology.
Jennifer Carlson, associate vice president for external relations & advocacy at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, was named inaugural chair of the National Comprehensive Cancer Network's Government Affairs Committee.
Twelve partner institutions from the United States and Canada are collaborating to develop novel treatments to improve quality of life and long-term survival for patients fighting malignant brain tumors.
The American Society of Clinical Oncology published a position statement on state drug repository programs, outlining ASCO's support for drug repository programs solely for oral medications, provided they are maintained within a closed system.
